Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Choriocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

saracatinib 1merphos 1cediranib 1carotuximab 1Pemetrexed 1Methotrexate 1Leucovorin 1Dactinomycin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Choriocarcinoma × carotuximab × Clear all
NCT02396511 2019-06-11

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Tracon Pharmaceuticals Inc.

Phase 2 Completed
2 enrolled 10 charts

Choriocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡